NTI Stock Overview
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia.
Notes are coming soon
Neurotech International Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.071|
|52 Week High||AU$0.13|
|52 Week Low||AU$0.044|
|1 Month Change||2.90%|
|3 Month Change||-33.95%|
|1 Year Change||39.22%|
|3 Year Change||688.89%|
|5 Year Change||-61.62%|
|Change since IPO||-75.09%|
Recent News & Updates
Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?Jan 21
Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?Oct 06
Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn SituationMay 18
We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn RateDec 21
Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth PlansSep 04
Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling SharesDec 08
|NTI||AU Medical Equipment||AU Market|
Return vs Industry: NTI exceeded the Australian Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: NTI exceeded the Australian Market which returned 3.5% over the past year.
|NTI Average Weekly Movement||9.5%|
|Medical Equipment Industry Average Movement||9.7%|
|Market Average Movement||8.5%|
|10% most volatile stocks in AU Market||15.7%|
|10% least volatile stocks in AU Market||3.5%|
Stable Share Price: NTI is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: NTI's weekly volatility (9%) has been stable over the past year.
About the Company
|2016||n/a||Peter James Griffiths||https://www.neurotechinternational.com|
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism.
Neurotech International Limited Fundamentals Summary
|NTI fundamental statistics|
Is NTI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NTI income statement (TTM)|
|Cost of Revenue||AU$34.05k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Jan 30, 2023
|Earnings per share (EPS)||-0.004|
|Net Profit Margin||-553.35%|
How did NTI perform over the long term?See historical performance and comparison